Medical-device development and patient contact

Which finished-product evidence supports a medical-use, implant, sterility or patient-contact representation, if any is made?

The company publishes no finished-product evidence for a medical use, an implant, a sterility claim or patient contact, and its Medical page describes a Research Application, not a finished product.

The label for the NanoFlashing™ Air Filter states that the filter is not a medical device and is not intended to diagnose, treat, cure or prevent disease. The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. They also state: “A test of a material, component, sample, or prototype does not establish the safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, or performance of a finished product.” and that images and descriptions may show concepts or prototypes, which are not specifications, instructions, validation reports, recommendations, warranties, offers, promises, or commitments.

What the company does publish is named on the Validation page: the pathogens tested, the conditions tested, the institutes that tested them, the peer-reviewed paper by Gong, Or, Sze et al., Microbiology Spectrum 12(9), e0409723, American Society for Microbiology, doi:10.1128/spectrum.04097-23, and, for the air-filtration, certification and safety records, the issuing body and the number for each. The paper reports laboratory results on SARS-CoV-2 in contact with treated textile, on aerosolised bovine coronavirus passed through a test filter in a wind tunnel, and on bacterial viability on treated textiles; each result belongs to the article that was tested.

Source: C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/; C-POLAR — Validation, https://cpolar.tech/validation/; NanoFlashing™ Air Filter label, About this product. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 21 September 2026.

Would integrating the material change the intended use of an existing medical device?

What the intended use of a device is, and whether a change alters it, is determined by the device's own sponsor under the rules that apply to that device.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. They also state: “A test of a material, component, sample, or prototype does not establish the safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, or performance of a finished product.” and that images and descriptions may show concepts or prototypes, which are not specifications, instructions, validation reports, recommendations, warranties, offers, promises, or commitments. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” The Terms also state: “Nothing on the Site authorizes anyone to manufacture, integrate, market, resell, or describe a product as C-POLAR-enabled.”

Source: C-POLAR — Terms of Use, sections 4 and 5, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/.

Reviewed on 21 September 2026.

Is the proposed component intended to contact intact skin, compromised skin or an internal fluid path?

The company publishes no contact category for a component, because it offers no medical component.

The Medical devices chapter states that the NanoFlashing™ Medical Device has a permanent positive polarity, a fixed positive charge. The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. What the company states about skin contact is a certification and a laboratory study of the material: NanoFlashing™ is certified to OEKO-TEX® Standard 100, Product Class II, the class for products in direct contact with skin, under OEKO-TEX Service GmbH, Certificate 17.0.25812, and Product Safety Labs, Study 65324, completed 31 January 2024, reported that the material it tested “is not considered to be a contact sensitizer”. A copy may be made available on our review of the request.

Those records cover what they cover, and neither is a clearance for a device, for compromised skin or for an internal fluid path. Certificate 17.0.25812 can be checked at source in OEKO-TEX’s public label check.

Source: C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/; C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65324, completed 31 January 2024; C-POLAR — Terms of Use, section 4, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page; OEKO-TEX Label Check, read 19 September 2026, https://www.oeko-tex.com/en/label-check.

Reviewed on 21 September 2026.

Does the duration of patient contact change the required biological evaluation?

What a device sponsor must hold or submit is decided by that sponsor and by the authority it submits to, and the company gives no regulatory advice.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.”

What the company states about its own testing is on the Validation page. The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Those are studies of the material under the guidelines named, and they are not a biological evaluation of a finished device.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 4 and 5, https://cpolar.tech/terms/. A copy may be made available on our review of the request.

Reviewed on 21 September 2026.

Can the treatment tolerate the intended sterilisation process?

The company publishes no result for that exposure.

The conditions listed on the Validation page are heavy dust loaded, fast air flow, used filter for 1 year, after 60 washes, after 2 years of storage, and after 60C for 64 days. A sterilisation process is not among them, and the company publishes no sterilisation study and no compatibility statement for one. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 21 September 2026.

Does sterilisation alter the material's functional properties even if it remains physically intact?

The company publishes no result for that exposure.

The conditions listed on the Validation page are heavy dust loaded, fast air flow, used filter for 1 year, after 60 washes, after 2 years of storage, and after 60C for 64 days. A sterilisation process is not among them, and the company publishes no before-and-after measurement for one. NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 21 September 2026.

Can the material be supplied with documented cleanliness limits appropriate to the proposed device?

The company publishes no cleanroom classification, no shedding measurement and no packaging cleanliness class.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. A cleanliness limit for delivered material is a term of the agreement that governs the delivery, and C-POLAR publishes none.

The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.”

Source: C-POLAR — Terms of Use, sections 4, 5 and 6, https://cpolar.tech/terms/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 21 September 2026.

Would packaging aging affect sterile-barrier integrity for a device containing the material?

The company publishes no result for that exposure.

The company publishes no packaging-ageing result and no sterile-barrier result. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the material interact with drugs passing through a proposed fluid-contact device?

The company publishes no result for that exposure.

The company publishes no interaction study. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Could it bind a therapeutic substance that the device is meant to deliver?

The company publishes no result for that exposure.

The company publishes no binding study. What it states about the mechanism is that NanoFlashing™ attracts negatively charged particles through electrostatic attraction, and that the filter captures airborne particles mechanically and by electrostatic attraction. The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, section 2.5, issued by NF Technical Products Inc.; C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does a proposed wound-contact use require evidence about healing rather than surface performance alone?

The Terms of Use state that a laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health, and: “Do not use Site Content to diagnose, treat, or make a patient-care or infection-control decision.”

The label for the NanoFlashing™ Air Filter states that the filter is not a medical device and is not intended to diagnose, treat, cure or prevent disease.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms also state: “Do not delay or replace professional care because of Site Content.” The company publishes no wound-contact result and no healing outcome of any kind. A laboratory result on an organism is not a medical conclusion.

Source: C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/; NanoFlashing™ Air Filter label, About this product.

Reviewed on 21 September 2026.

Can the material change a device's electrical or electromagnetic safety assessment?

The Terms of Use state that a test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it, and that construction, processing, storage, wear, cleaning, other components, and actual use may change the result.

The filter is passive. It draws no power, and it has no power supply, electrode, lamp or reservoir. The polarity is a positive electric charge at rest. A charge is a physical property. It is not a substance or a mixture of substances. This site publishes no electrical-safety or electromagnetic-compatibility test for any product.

The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” Whether a device's electrical assessment changes is determined by the sponsor of that device.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.2, 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Would a ventilator accessory containing the material alter delivered pressure or volume?

The Terms of Use state that a test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it, and that construction, processing, storage, wear, cleaning, other components, and actual use may change the result.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The company publishes no result for a ventilator accessory and no pressure or volume measurement for any product.

The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” NanoFlashing™ is a technology; the name, rating and sale of a product that carries it are set by that product's maker and seller.

Source: C-POLAR — Terms of Use, sections 3, 4 and 5, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/.

Reviewed on 21 September 2026.

Does a device sponsor need separate evidence for extractables and leachables?

What a device sponsor must hold or submit is decided by that sponsor and by the authority it submits to, and the company gives no regulatory advice.

The company publishes no extractables study and no leachables study. The company's statement that the filter emits nothing into the air passing through it is about a filter in use, and it is not an extractables or leachables result.

Source: Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 21 September 2026.

Can a material supplier support a regulator's confidential review without disclosing trade secrets publicly?

A review that needs more than the company's published pages is arranged in writing, and material sent through a general Site form is not treated as confidential.

The Terms of Use state: “Do not send confidential, proprietary, patient, or trade-secret information through a general Site form. C-POLAR does not accept a duty of confidentiality for material sent through a general Site form unless a Separate Agreement covering that material is already in force.” A Separate Agreement is a written agreement signed by an authorized C-POLAR officer.

Each numbered report the company cites is named with its institution and number, and with its date and standard where the report gives them.

Source: C-POLAR — Terms of Use, sections 1 and 10, https://cpolar.tech/terms/; C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Would reprocessing a reusable medical device alter the supported treatment function?

The company publishes no result for that exposure.

The conditions listed on the Validation page are heavy dust loaded, fast air flow, used filter for 1 year, after 60 washes, after 2 years of storage, and after 60C for 64 days. A reprocessing cycle for a reusable device is not among them, and the company publishes no reprocessing study. The one article the company labels is replaced rather than reprocessed: “Do not wash, vacuum, brush, blow out or reuse this filter.” The Terms of Use state: “A reported result describes only what the identified test found.” The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Is the material's quality agreement compatible with the device maker's change-control obligations?

For a prospective partner, a commitment from C-POLAR is one stated in a Separate Agreement, which is a written agreement signed by an authorized C-POLAR officer.

The Terms of Use state that accessing the Site or contacting C-POLAR through the Site does not create a partnership, agency, joint venture, distribution right, supply commitment, license, exclusive right, or other business relationship, and that a prospective partner may rely only on a commitment stated in a Separate Agreement. They also state that where these Terms conflict with a Separate Agreement or an express written C-POLAR warranty, that document controls. C-POLAR publishes no quality agreement and no change-notification commitment.

Source: C-POLAR — Terms of Use, sections 1, 5 and 6, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Can the device manufacturer trace implanted or long-term-contact components to a specific supplied lot?

Production records and release decisions belong to the manufacturing partner that makes the product, and C-POLAR publishes none of them.

Every commercial NanoFlashing™ product is made by a manufacturing partner, in their facility, in their format, and lot identification on delivered material is a term of the agreement that governs the delivery. The Medical devices chapter describes a Research Application, and it does not describe a finished product currently available from C-POLAR for that use.

What a device manufacturer must trace, and how far back, is decided by that manufacturer under the rules that apply to it.

Source: C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Terms of Use, sections 4 and 6, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the product's design history identify the risk created by adding the treated material?

The Terms of Use state that a test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it, and that construction, processing, storage, wear, cleaning, other components, and actual use may change the result.

A design history file belongs to the manufacturer that opened it, and C-POLAR holds none. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The Medical devices chapter describes a Research Application, and it does not describe a finished product currently available from C-POLAR for that use.

Source: C-POLAR — Terms of Use, sections 3, 4 and 5, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Would a clinical investigation be needed for the proposed device claim?

What a device sponsor must hold or submit is decided by that sponsor and by the authority it submits to, and the company gives no regulatory advice.

The Terms of Use state that, as of their effective date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications, and that they do not describe finished products currently available from C-POLAR for those uses. The Terms of Use state that a laboratory reduction in a virus, bacterium, fungus, particle, or other endpoint does not establish a clinical benefit, fewer infections, disease prevention or treatment, or improved health, and: “Do not use Site Content to diagnose, treat, or make a patient-care or infection-control decision.” The company publishes no clinical investigation and no clinical result of any kind.

Source: C-POLAR — Terms of Use, sections 3 and 4, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/. A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Reviewed on 21 September 2026.

Can a component supplier's safety testing replace any part of the finished device's usability assessment?

The Terms of Use state that a test of C-POLAR material, a component, or a prototype does not establish the performance of a finished product that incorporates it, and that construction, processing, storage, wear, cleaning, other components, and actual use may change the result.

They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.” A usability assessment is made on the finished product, with its own users, and no material test replaces any part of it.

The company publishes no usability study, no comprehension test and no record of instructions tried with first-time users.

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/.

Reviewed on 21 September 2026.

Does the FDA's medical-device clearance pathway (510(k)) apply to the NanoFlashing™ Medical vertical?

The company publishes no FDA position, 510(k) or other, for the Medical vertical, and its Terms of Use describe that chapter as a Research Application.

The Terms of Use state: “As of the Effective Date, the Water, Textiles, Food packaging, and Medical devices chapters describe Research Applications. They do not describe finished products currently available from C-POLAR for those uses.” The Medical page states: “The NanoFlashing™ Medical Device has a permanent positive polarity, a fixed positive charge.” The company's two classification statements, under FIFRA in the United States and under Regulation (EU) No 528/2012, are written for the NanoFlashing™ Air Filter, a panel air filter for forced-air heating, ventilation and air-conditioning systems. The Terms of Use also state: “A test of a material, component, sample, or prototype does not establish the safety, efficacy, suitability, durability, compatibility, manufacturability, scalability, or performance of a finished product.”

Source: C-POLAR — Terms of Use, section 4, https://cpolar.tech/terms/; C-POLAR — NanoFlashing™ Medical, https://cpolar.tech/medical/; Statement of Classification for the NanoFlashing™ Air Filter, section 1.2, issued by NF Technical Products Inc.; Statement of Regulatory Status for the NanoFlashing™ Air Filter, section 1.2, C-POLAR Technologies, Inc., 11 September 2026.

Reviewed on 21 September 2026.